



الشركة القطرية الألمانية
للمستلزمات الطبية
(ش.م.ع.ق)

**QATARI GERMAN FOR
MEDICAL DEVICES
COMPANY**

www.qgmd.com

Contents



[Disclaimer](#)

[QGMD Production](#)

[Financial Statements Review as of September 30,2020](#)

[Trading Products](#)

[Manufacturing](#)



Disclaimer

The following presentation is made only to, and is directed only at, persons to whom such a presentation may lawfully be communicated (“relevant persons”). Any person who is not a relevant person should not act or rely on this presentation or any of its contents.

This presentation contains forward-looking statements that are subject to risks and uncertainties, including statements about QGMD’s beliefs and expectations.

These forward-looking statements are based on assumptions that QGMD has made in light of its experience in the industry in which it operates, as well as its perceptions of historical trends, current conditions, expected future developments and other factors which QGMD believes are appropriate under the circumstances.

Prospective investors should understand that these statements are not guarantees of future performance or results.

Due to these factors, QGMD cautions that prospective investors should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made.

New risks and uncertainties arise from time-to-time, and it is impossible to predict these events or how they may affect QGMD.

QGMD Production Facilities

QGMD production of Syringes and IVC's Continues running through 2020 Q3 un-affected with the Covid-19 pandemic . Thanks to the Strict hygienic and infection control measures , that was implemented since the very beginning of the pandemic



**Interim Condensed
Financial Statements
Review Report for
the Nine Months
Ended
September 30, 2020**



STATEMENT OF FINANCIAL POSITION AS of September 30, 2020



	30,Sept 2020 (QR.) Reviewed	31, December 2019 (QR.)Audited
ASSETS		
NON-CURRENT ASSETS		
Property, plant, equipment and capital work in progress	112,218,865	116,286,878
Investment properties	12,590,000	12,590,000
Right-of-use assets	102,224	106,871
Intangible assets	10,329,937	10,329,937
Total Non-Current Assets	135,241,027	139,313,686
CURRENT ASSETS		
Inventories	22,266,250	11,271,253
Accounts and other receivables	17,291,727	2,581,390
Cash in hand and at banks	2,596,086	961,908
Total Current Assets	42,154,063	14,814,551
Total Assets	177,395,090	154,128,237
	=====	=====
EQUITY AND LIABILITIES		
EQUITY		
Share capital	115,500,000	115,500,000
Legal reserve	30,343,120	30,343,120
Revaluation reserve	11,999,694	11,999,694
Accumulated losses	(127,792,977)	(127,195,066)
Net Equity	30,049,836	30,647,748
NON-CURRENT LIABILITIES		
Employees' end of service benefits	1,012,973	997,117
Loans and borrowings - long term portion	114,281,803	99,968,055
Lease liabilities -long term portion	89,215	97,529
Total Non-Current Liabilities	115,383,991	101,062,701
CURRENT LIABILITIES		
Loans and borrowings - short term portion	10,967,641	4,800,102
Lease liabilities -short term portion	8,314	8,032
Accounts and other payables	5,866,349	2,455,014
Bank overdraft	15,118,958	15,154,640
Total Current Liabilities	31,961,262	22,417,788
Total Liabilities	147,345,253	123,480,489
Total Equity and Liabilities	177,395,090	154,128,237



INTERIM CONDENSED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (REVIEWED) FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2020	Growth Ratio (%)	Nine months ended September 30,2020 (QR.) (Reviewed)	Nine Months ended September 30,2019 (QR.) (Reviewed)
Revenue	+240.7%	21,372,860	6,272,526
Operating cost (Except Depreciation)		(15,439,401)	(4,075,780)
		_____	_____
Gross profit(%)	27.7%	5,933,459	2,196,746
Other income	+62.2%	2,861,819	1,764,339
Selling and distribution expenses	-20.89%	(241,387)	(305,135)
General and administrative expenses	-35.89%	(3,284,641)	(5,123,739)
Depreciation and amortization	-0.77%	(4,112,047)	(4,144,042)
Finance cost	-38.55%	(1,755,114)	(2,856,191)
		_____	_____
Income (Loss) for the period	-93%	(597,911)	(8,468,022)
		_____	_____
Other comprehensive income		-0-	-0-
		_____	_____
Total comprehensive (loss) for the period		(597,911)	(8,468,022)
		=====	=====
EBITDA		5,269,250	(1,467,789)
(Loss) per share			
Basic and diluted (loss) per share (QR.)	-93%	(0.005)	(0.073)
		=====	=====

HMC Infection Control Week 2020



Certificate of Appreciation for Sponsorship

This certificate is awarded to

Qatari German Medical Devices Co.

With appreciation, respect and gratitude, in recognition of your support in becoming a sponsor for HMC Infection Control Week 2020.


Dr. Jamecla Al Ajmi,
Sr. Consultant Infectious Diseases
Executive Director, Corporate Infection Prevention & Control


- QGMD participated as a Sponsor in HMC Infection control week 2020 .
- QGMD was able to ensure the supply of 200 HEPA filter machines during the covid-19 pandemic , which was a challenging task . As these devices are key machines in the infection control process .

New Products

QGMD announced the availability of the unique **80% Liquid sanitizer** .

It is Tested in QGMD laboratory and manufactured in accordance with the WHO guidelines .





Syringe for COVID-19 Vaccine

- QGMD is committed to supply Syringe for COVID-19 Vaccine.
- QGMD started producing the syringes needed for the COVID-19 vaccine , to keep strategic stock for the Qatari Population .



Thank you

Qatari German for Medical Devices

October, 2020

www.qgmd.com

